Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock

BioMarin Pharmaceutical (BMRN) is highlighted by Zacks as a potential growth investment, despite its current #3 (Hold) Zacks Rank. The company exhibits robust underlying metrics, including an 'A' VGM score and a 'B' Growth Style Score, supported by a forecasted 23% year-over-year earnings growth for the current fiscal year. Furthermore, analysts have recently revised FY2025 earnings estimates upwards, and BMRN boasts a strong historical average earnings surprise of 32.8%, suggesting it warrants consideration for growth-oriented portfolios.

Analysis

BioMarin Pharmaceutical (BMRN) presents a mixed but compelling profile according to the provided analysis. While the stock holds a neutral Zacks #3 (Hold) rank, its underlying quantitative metrics suggest strong growth potential. The company scores an 'A' on the composite VGM Score and a 'B' for Growth, supported by a significant 23% year-over-year earnings growth forecast for the current fiscal year. Furthermore, BMRN has demonstrated a consistent ability to outperform expectations, boasting an average earnings surprise of +32.8%. Looking ahead, the outlook for fiscal 2025 appears to be improving, as two analysts have revised their earnings estimates upward in the last 60 days, settling the consensus at $4.33 per share. This combination of a strong growth forecast, positive earnings revisions, and a history of beating estimates positions BMRN as a noteworthy candidate for portfolios focused on growth, despite its current neutral rating.

Key Decisions for Investors

• Investors should consider the disconnect between the neutral Zacks #3 (Hold) rank and the strong underlying growth metrics, such as the 23% projected earnings growth and 'A' VGM score, which may present an opportunity for growth-focused portfolios.
• Given the company's significant historical average earnings surprise of +32.8% and recent upward revisions to FY2025 estimates, monitoring upcoming earnings announcements for continued outperformance is critical, as this could act as a key catalyst for the stock.
• The neutral 'Hold' rating itself should be weighed carefully, as it may imply that the market has already priced in the strong growth outlook or that other factors not detailed in the report are limiting near-term upside potential.